Ensuring the intestinal health of piglets
Animab is a biotech company designed to address the changing needs of livestock production. Using proprietary research discoveries, Animab targets gastrointestinal infections. The interdisciplinary team integrates cutting-edge research in animal science and biotechnology for product breakthroughs, cost-efficiencies and sustainability in animal health. Led by experts in a range of relevant domains from vaccines, biotechnology, business management and international marketing, Animab is dedicated to offering a safe and sustainable way to ensure better animal performance.
Animab was founded in 2020 as a spin-off of the VIB and its partner universities Ghent University (UGent) and Vrije Universiteit Brussel (VUB), backed by a solid European investor consortium. In a collaborative effort with VIB, VUB and the Ghent University Faculty of Veterinary Medicine, Animab further improved these antibodies to target with speed and precision specific intestinal pathogens in livestock without altering the healthy microbiome.
Animab continues to collaborate with these top academic research groups to expand the high precision biological resources available to protect young animals.
